

 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10 016,228
Filing Date		November 2, 2001	
First Named Inventor		Sabb et al.	
Group An Unit		1624	
Examiner Name		B. Coleman	
Attorney Docket Number		AM100318	
Sheet	1	of	2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If known)			class subclass
BC	1.	2002 0107242	A1	American Home Products Corp.	08-08-2002	514 219
BC	2.	5,834,454		Sumitomo Pharmaceuticals Co.	11-10-1998	514 183
BC	3.	2002 0173503		Robichaud et al.	11-21-2002	514 211.1
BC	4.	3,714,149		Hester J. The Upjohn Company	01-30-1973	260 239.3
BC	5.	3,417,101		Bell et al.	12-17-1968	260 328
BC	6.	3,329,676		S.C. Bell et al.	07-04-1967	260 239.3
BC	7.	5,045,545		Glaxo Group Ltd. Boys et al.	09-03-1991	514 284
BC	8.	4,997,831		Glaxo Group Ltd. Boys et al.	03-05-1991	514 211
BC	9.	3,466,274		Rene R. DeRidder	09-09-1969	260 239
BC	10.	3,335,134		Sandoz Inc. Frey et al.	08-08-1967	260 239.3
BC	11.	3,296,252		Sandoz Inc. Frey et al.	01-03-1967	260 239.3
BC	12.	3,235,564		G.D. Seale & Co. Wagner et al.	02-15-1966	260 327
BC	13.	2003/0050300	A1	William W. McWhorter Jr.	03-13-2003	514 211.1

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (If known)		
BC	14.	WO	96/29316	A1	Wikstrom	09-26-1996
BC	15.	WO	00/35922	A1	American Home Products Corp.	06-22-2000
BC	16.	WO	02/08186	A2	Merck Frosst Canada & Co.	01-31-2002
BC	17.	WO	02/42304	A2	Wyeth	05-30-2002
BC	18.	WO	02/059124	A2	Bristol-Myers Squibb Co.	08-01-2002
BC	19.	JP	10-237073 (U.S. Equiv. 5,834,454)		Sumitomo Pharmaceuticals	09-08-1998
BC	20.	WO	00/77002	A1	DuPont Pharmaceuticals Co.	12-21-2000
BC	21.	WO	90/15058	A1	The Upjohn Company	12-13-1990
BC	22.	WO	02/059129	A2	Bristol-Myers Squibb Co.	08-01-2002
BC	23.	WO	99/67219	A1	Elan Pharmaceuticals, Inc.	12-29-1999
BC	24.	WO	99/66934	A1	Elan Pharmaceuticals, Inc.	12-29-1999
BC	25.	SU	930902		S. Ordzhonikidze	11-19-1982
BC	26.	WO	00/64899	A1	Pharmacia & Upjohn Co.	11-02-2000
BC	27.	WO	97/31000	A1	Chiroscience Ltd.	08-28-1997
BC	28.	EP	0357417	A1	Glaxo Group Ltd.	03-07-1990
BC	29.	EP	0344015	A2	Glaxo Group Ltd.	11-29-1989
BC	30.	WO	01/12603	A1	Vernalis Research Ltd.	02-22-2001
BC	31.	WO	02/36596	A2	Wyeth	05-10-2002
BC	32.	WO	02/42304	A2	Wyeth	05-30-2002
BC	33.	WO	97/30999	A1	Chiroscience Ltd.	08-28-1997

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issuе number(s), publisher, city and/or country, where published	T
BC	34.	P.J. COWEN et al., Nature 376, 557 (August 1995).	<input type="checkbox"/>
BC	35.	A.J. ROBICHAUD et al., Annual Reports in Medicinal Chemistry, 35, 11-20 (2000).	
BC	36.	D. HOYER et al., Pharmacology & Experimental Therapeutics 46(2), 157-203 (1994).	

Examiner Signature	Brenda Coleman	Date Considered	Feb. 22, 2004
--------------------	----------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

** structures only

Substitute for form 1443 PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary.)

Sheet 2 of 2

Complete if Known

Application Number	10 016,228
Filing Date	November 2, 2001
First Named Inventor	Sabb et al.
Group Art Unit	1624
Examiner Name	B. Coleman
Attorney Docket Number	AM100318

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
BC	37.	L. TECOTT et al., Nature, 374, 542-546 (April 1995).	
BC	38.	D.H. KIM, J. Heterocycl. Chem., 12, 1323-1324 (December 1975).	
BC	39.	M.J. BISHOP et al., Expert Opin. Ther. Patents, 13(11), 1691-1705 (2003).	
BC	40.	SHUNJI NARUTO et al., Tetrahedron Letters, 39, 3399-3402 (1975).	
BC	41.	A.N. GRINEV et al., Chem. Heterocycl. Compd., 19(9), 959-961 (1983).	<input type="checkbox"/>
BC	42.	A.N. GRINEV et al., Chem. Heterocycl. Compd., 19(12), 1312-1315 (1983).	
BC	43.	E.V. LAMANOVA et al., Pharm. Chem., J., 23(2), 113-115 (1989).	
BC	44.	D.H. KIM et al., Journal of Medicinal Chemistry, 20(2), 209-212 (1977).	
BC	45.	L. TOSCANO et al., J. Heterocyclic Chem., 13, 475-480 (1976).	
BC	46.	A. KATRITZKY et al., Synthesis, 10, 1487-1490 (1998).	
BC	47.	F. GATTA et al., Edizione Scientifica, 30(8), 631-641 (1975).	
BC	48.	W. LOPES et al., Journal of Brazilian Chemical Society, 4(1), 34-39 (1993).	

Examiner Signature	Brenda Coleman	Date Considered	Feb. 22, 2004
--------------------	----------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

** structures only